Literature DB >> 9839694

Abnormal directed migration of blood polymorphonuclear leukocytes in rheumatoid arthritis. Potential role in increased susceptibility to bacterial infections.

F Aglas1, J Hermann, G Egger.   

Abstract

Rheumatoid arthritis (RA) patients are at higher risks of bacterial infection than healthy subjects. Polymorphonuclear leukocytes (PMN) are the first line of nonspecific cellular defence against these infections. We tested the hypothesis that abnormal directed migration of PMN may be one reason for the increased infection rate of RA patients. PMN migration was investigated in 68 peripheral blood samples of 15 RA patients compared with 64 samples of healthy controls in a novel whole blood in vitro membrane filter assay. The migration of PMNs from RA patients and controls was stimulated using the bacterial chemoattractant N-formyl-methionyl-leucyl-phenylalanine (fMLP). Unstimulated PMN migration of RA patients was increased compared with healthy controls as measured by the following parameters: (a) absolute number of migrant PMNs (1954+/-87 vs. 1238 +/-58 PMN/mm2), (b) percentage of PMNs migrated into the filter (total migration index, TMI) (28.6+/-0.9 vs. 24.0+/-0.8%), (c) the distance half the migrating PMNs had covered (distribution characteristic, DC) (22.6+/-1.1 vs. 16.1+/-0.6 mm) and (d) the product of TMI and DC (neutrophil migratory activity, NMA) (669.0+/-45.0 vs. 389.0+/-18.9). fMLP stimulated PMNs of RA patients showed defective migration compared to unstimulated samples as shown by (a) a reduced number of migrant PMNs (1799+/-93 PMN/mm2), (b) lower TMI (26.1+/-0.9%), (c) unremarkable altered distribution characteristic (22.9+/-0.8 mm) and (d) significant reduced migratory activity (600.0+/-30.0). Our data suggest that the high incidence of infections in RA patients may partly be caused by defective migratory activity of PMNs to bacterial chemoattractants as demonstrated by fMLP.

Entities:  

Mesh:

Year:  1998        PMID: 9839694      PMCID: PMC1781821          DOI: 10.1080/09629359891333

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  29 in total

1.  Impaired actin polymerization and depolymerization in neutrophils from patients with thermal injury.

Authors:  H A Vindenes; R Bjerknes
Journal:  Burns       Date:  1997-03       Impact factor: 2.744

2.  Survivorship and death in rheumatoid arthritis.

Authors:  J Uddin; A S Kraus; H G Kelly
Journal:  Arthritis Rheum       Date:  1970 Mar-Apr

3.  The chemokinetic inhibitory factor (CIF) in serum of CLL patients: correlation with infection propensity and disease activity.

Authors:  A Siegbahn; B Simonsson; P Venge
Journal:  Scand J Haematol       Date:  1985-07

4.  Subnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: relation to complement catabolism and disease extent.

Authors:  J Elmgreen; T M Hansen
Journal:  Ann Rheum Dis       Date:  1985-08       Impact factor: 19.103

Review 5.  Release of inflammatory mediators from stimulated neutrophils.

Authors:  G Weissmann; J E Smolen; H M Korchak
Journal:  N Engl J Med       Date:  1980-07-03       Impact factor: 91.245

6.  Polymorphonuclear cell function in rheumatoid arthritis and in Felty's syndrome.

Authors:  G B Howe; J N Fordham; K A Brown; H L Currey
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

7.  Impaired polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis.

Authors:  D H Goddard; A P Kirk; J R Kirwan; G D Johnson; E J Holborow
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

8.  Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup.

Authors:  J P Vandenbroucke; H M Hazevoet; A Cats
Journal:  J Rheumatol       Date:  1984-04       Impact factor: 4.666

9.  Death rate and causes of death in RA patients during a period of five years.

Authors:  K Koota; H Isomäki; O Mutru
Journal:  Scand J Rheumatol       Date:  1977       Impact factor: 3.641

10.  Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis.

Authors:  A G Mowat; J Baum
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

View more
  6 in total

1.  Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections.

Authors:  M M Gaida; F Günther; C Wagner; H Friess; N A Giese; J Schmidt; G M Hänsch; M N Wente
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

2.  Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: comparison with various inflammation parameters.

Authors:  Gerd Egger; Reingard Aigner; Andreas Glasner; Herwig P Hofer; Heike Mitterhammer; Sieglinde Zelzer
Journal:  Intensive Care Med       Date:  2004-01-16       Impact factor: 17.440

3.  Rheumatoid peripheral blood phagocytes are primed for activation but have impaired Fc-mediated generation of reactive oxygen species.

Authors:  Anna-Marie Fairhurst; Paul K Wallace; Ali S M Jawad; Nicolas J Goulding
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

4.  Neutrophils: the forgotten cell in JIA disease pathogenesis.

Authors:  James N Jarvis; Kaiyu Jiang; Howard R Petty; Michael Centola
Journal:  Pediatr Rheumatol Online J       Date:  2007-06-13       Impact factor: 3.054

5.  Habitual physical activity is associated with the maintenance of neutrophil migratory dynamics in healthy older adults.

Authors:  David B Bartlett; Oliver Fox; Clare L McNulty; Hannah L Greenwood; Laura Murphy; Elizabeth Sapey; Martin Goodman; Nicola Crabtree; Cecilie Thøgersen-Ntoumani; James P Fisher; Anton J M Wagenmakers; Janet M Lord
Journal:  Brain Behav Immun       Date:  2016-02-27       Impact factor: 7.217

6.  Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Francesca Minonzio; Paola Bonara; Andrea Doria; Mario Carrabba
Journal:  Arthritis Res Ther       Date:  2005-01-10       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.